Sanofi (SNY) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sanofi showcases the effectiveness of their infant RSV vaccine, Beyfortus, at IDWeek 2024, with data demonstrating over 80% real-world effectiveness in preventing disease and hospitalization. Beyfortus, which is approved in several regions including the US and EU, is designed to protect all infants through their first RSV season, with new manufacturing lines established to meet global demand.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
